Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in ...

Sales of Danish drugmaker Novo Nordisk 's Wegovy and U.S. rival Eli Lilly's Mounjaro in India doubled in July from a month ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in ...

Eli Lilly's experimental weight loss pill, orforglipron, demonstrated an average weight loss of 12% in a late-stage trial, ...

Novo Nordisk’s outgoing CEO, Lars Fruergaard Jorgensen, has warned that layoffs at the Danish pharmaceutical giant could be ...

Lilly has also said it has begun manufacturing the drug in order to stockpile supply ahead of a commercial launch, which should help avoid shortages experienced when early demand for the injectables ...

Wegovy, a brand name for semaglutide, is a GLP-1 inhibitor medication that targets the parts of the brain that regulate ...

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

While Novo Nordisk has gotten a lot of attention for its obesity/weight-loss drug Wegovy in recent years, Novo Nordisk is ...

Originally developed to treat type 2 diabetes and medical obesity, GLP-1 receptor agonists like tirzepatide and semaglutide ...

Eli Lilly & Co.’s experimental pill helped patients shed roughly 11% of their body weight, about 25 pounds, in a late-stage ...